Sugi Predict

Sugi Predict / Targets / FUS

FUS

RNA-binding protein FUS · P35637 · FUS on Sugi Atlas →

0 patent compounds predicted against FUS, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to FUS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) PHASE3ACTIVE_NOT_RECRUITING
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS PHASE3RECRUITING
Lurbinectedin in FET-Fused Tumors PHASE1/PHASE2RECRUITING
Colchicine for Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Memantine Therapy in Amyotrophic Lateral Sclerosis PHASE2COMPLETED
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD PHASE1/PHASE2RECRUITING
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS) PHASE2COMPLETED
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau PHASE1NOT_YET_RECRUITING
[18F]ACI-19626 PET in TDP-43 Proteinopathies EARLY_PHASE1RECRUITING
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis EARLY_PHASE1UNKNOWN
Study on the Safety and Efficacy of RAG-21 in the Treatment of Amyotrophic Lateral Sclerosis Patients With FUS Gene Mutations EARLY_PHASE1NOT_YET_RECRUITING
Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS nanCOMPLETED
A Study to Evaluate the Performance of a Diagnostic Test in ALS nanUNKNOWN
Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN
Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis nanCOMPLETED
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy nanRECRUITING
Progression Follow up of the First-degree Relatives of Patients With REM Sleep Behavior Disorder nanUNKNOWN
Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis nanNOT_YET_RECRUITING
Amyotrophic Lateral Sclerosis (ALS) Families Project nanRECRUITING
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches nanRECRUITING
Genetics of Familial and Sporadic ALS nanCOMPLETED
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) nanCOMPLETED
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation nanCOMPLETED
Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type nanACTIVE_NOT_RECRUITING
Genomic Translation for Amyotrophic Lateral Sclerosis Care nanCOMPLETED
Predict to Prevent PGRN Disease nanWITHDRAWN
Epidemiological Study in FRONtoTemporal Dementia nanCOMPLETED
Familial Aggregation and Biomarkers in REM Sleep Behaviour Disorder. nanUNKNOWN
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a FUS binder may also engage these)

ProteinNameSimilarity
P56959 — 1.000 P56959 →
Q28009 — 1.000 Q28009 →
Q61545 — 0.989 Q61545 →
EWSR1 RNA-binding protein EWS 0.988 landscape →
Q27294 — 0.985 Q27294 →
P48810 — 0.985 P48810 →
TAF15 TATA-binding protein-associated factor 2N 0.984 landscape →
Q94KD0 — 0.984 Q94KD0 →
Q22037 — 0.980 Q22037 →
A7VJC2 — 0.980 A7VJC2 →
Q5RBU8 — 0.979 Q5RBU8 →
P51992 — 0.979 P51992 →
P21522 — 0.979 P21522 →
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1 0.978 landscape →
HNRNPA3 Heterogeneous nuclear ribonucleoprotein A3 0.977 landscape →
Q7ZWA3 — 0.975 Q7ZWA3 →
Q9TTV2 — 0.975 Q9TTV2 →
Q6URK4 — 0.975 Q6URK4 →
P17130 — 0.975 P17130 →
Q8BG05 — 0.975 Q8BG05 →
HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0 0.975 landscape →
P51968 — 0.975 P51968 →
P51989 — 0.975 P51989 →
P51990 — 0.975 P51990 →
A5A6M3 — 0.975 A5A6M3 →
P38159 — 0.975 P38159 →
Q4R7F0 — 0.974 Q4R7F0 →
Q32P51 — 0.974 Q32P51 →
HNRNPA2B1 Heterogeneous nuclear ribonucleoproteins A2/B1 0.973 landscape →
Q2HJ60 — 0.972 Q2HJ60 →